Newborn Screening for Lysosomal Storage Disorders

被引:9
作者
Anderson, Sharon [1 ,2 ]
机构
[1] Rutgers Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, Pediat Genet, 89 French St, New Brunswick, NJ 08901 USA
[2] Rutgers Sch Nursing, Newark, NJ USA
关键词
Lysosomal storage disorder; lysosomal storage disease; lysosomal enzyme disorder; newborn screening; KRABBE-DISEASE; MUCOPOLYSACCHARIDOSES;
D O I
10.1016/j.pedhc.2017.04.016
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Lysosomal storage disorders (LSDs) are a heterogeneous group of approximately 50 rare inherited metabolic conditions that result from enzyme deficiencies that interfere with lysosome function. Although often grouped together, there is great variability regarding age of onset, severity, treatment, and outcomes for each disorder and subtype. Currently, laboratory methods are available to test newborns for seven of these conditions. Although newborn screening programs remain state-based, each at a different phase of condition review and implementation, if newborn screening for LSDs has not yet been adopted by the state within which you practice, it likely will. Given the extremely low prevalence and limited provider familiarity with these conditions, this article provides an overview of LSDs and the seven conditions for which newborn screening is available. It offers information about each of the conditions including enzyme deficiency, mode of inheritance, incidence rates, types, clinical course, and available as well as potential treatment options.
引用
收藏
页码:285 / 294
页数:10
相关论文
共 44 条
[1]  
[Anonymous], 2001, METABOLIC MOL BASIS
[2]   Cumulative incidence rates of the mucopolysaccharidoses in Germany [J].
Baehner, F ;
Schmiedeskamp, C ;
Krummenauer, F ;
Miebach, E ;
Bajbouj, M ;
Whybra, C ;
Kohlschütter, A ;
Kampmann, C ;
Beck, M .
JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 (06) :1011-1017
[3]   The natural history of MPS I: global perspectives from the MPS I Registry [J].
Beck, Michael ;
Arn, Pamela ;
Giugliani, Roberto ;
Muenzer, Joseph ;
Okuyama, Torayuki ;
Taylor, John ;
Fallet, Shari .
GENETICS IN MEDICINE, 2014, 16 (10) :759-765
[4]  
Bezman L, 2001, ANN NEUROL, V49, P512, DOI 10.1002/ana.101.abs
[5]  
Clarke L. A., 2016, GENE REV
[6]   Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease [J].
Clayton, Nicholas P. ;
Nelson, Carol A. ;
Weeden, Timothy ;
Taylor, Kristin M. ;
Moreland, Rodney J. ;
Scheule, Ronald K. ;
Phillips, Lucy ;
Leger, Andrew J. ;
Cheng, Seng H. ;
Wentworth, Bruce M. .
MOLECULAR THERAPY-NUCLEIC ACIDS, 2014, 3 :e206
[7]  
Hirschhorn R., 2001, The Metabolic and Molecular Bases of Inherited Disease, P3389
[8]  
Ibrahim J., 2011, MEDSCAPE REFERENCE D
[9]  
Ierardi-Curto L., 2012, MEDSCAPE REFERENCE D
[10]  
Illinois Department of Public Health Genetics and Newborn Screening, ILL NEWB SCREEN PAN